While angiotensin II (ang II) has been implicated in the pathogenesis of cardiac cachexia (CC), the molecules that mediate ang II's wasting effect have not been identified. It is known TNF-α level is increased in patients with CC, and TNF-α release is triggered by ang II. We therefore hypothesized that ang II induced muscle wasting is mediated by TNF-α. Ang II infusion led to skeletal muscle wasting in wild type (WT) but not in TNF alpha type 1 receptor knockout (TNFR1KO) mice, suggesting that ang II induced muscle loss is mediated by TNF-α through its type 1 receptor. Microarray analysis identified cholesterol 25-hydroxylase (Ch25h) as the down stream target of TNF-α. Intraperitoneal injection of 25-hydroxycholesterol (25-OHC), the product of Ch25h, resulted in muscle loss in C57BL/6 mice, accompanied by increased expression of atrogin-1, MuRF1 and suppression of IGF-1/Akt signaling pathway. The identification of 25-OHC as an inducer of muscle wasting has implications for the development of specific treatment strategies in preventing muscle loss.
Introduction
About 1/3 of patients with congestive heart failure suffer from cardiac cachexia (CC), which is characterized by muscle weakness and atrophy (Khawaja et al., 2014; Mancini et al., 1992; von Haehling et al., 2007) . Patients with CC have a poor prognosis and there is no effective treatment for this condition, mainly due to the fact that mechanisms involved in CC remain largely unknown.
Clinical studies show that ang II is increased in patients with CC. We and others have shown that ang II infusion induces muscle wasting in rodents. However, ang II receptors are expressed at very low levels in adult skeletal muscle. Therefore, ang II induced muscle wasting may be mediated by other intermediate factors. It is well documented that TNF-α levels are increased in patients with CC (Cicoira et al., 2001; Doehner et al., 2007; Toth et al., 2006; Yende et al., 2006) . In monocrotaline induced rat heart failure model, myocyte apoptosis and muscle atrophy are associated with increased levels of ang II and TNF-α (Dalla Libera et al., 2001) . Blockade of ang II type 1 receptor with irbesartan prevented the increase of plasma TNF-α levels and inhibited muscle atrophy (Dalla Libera et al., 2001) . Despite the correlation between ang II and TNF-α, no studies to date have examined this relationship directly to determine whether ang II induced muscle wasting is mediated by TNF-α.
TNF-α has two receptors, TNFR1 and TNFR2. Previous studies suggest that TNF-α induced muscle wasting is mediated by TNFR1 (Hardin et al., 2008; Llovera et al., 1998) . We therefore took advantage of the TNFR1 knockout mouse model (TNFR1KO) to directly test the hypothesis that loss of TNFR1 would prevent ang II induced muscle wasting. We demonstrated that ang II induced muscle wasting is mediated by TNF-α through TNFR1. Furthermore, we identified Ch25h as the downstream target of TNF-α that mediate ang II's wasting effect. Ch25h EBioMedicine 16 (2017) is an enzyme that convert cholesterol into , which has been shown to inhibit myogenesis via down regulation of IGF-1 signaling (Romanelli et al., 2009) . We showed that intraperitoneal injection of 25-OHC resulted in muscle loss in C57BL/6 mice, accompanied by increased expression of atrogin-1, MuRF1 and suppression of IGF-1/Akt signaling and reduced phosphorylation of GSK3-beta. Our data suggest that ang II infusion activates TNF/25-OHC pathway, leading to increased expression of markers of proteolysis, apoptosis and impaired myogenesis through GSK3-beta activation.
Materials and Methods

Mice
Male C57BL/6 mice from Model Animal Research Center of Nanjing, and TNFR1 knockout (TNFR1KO) mice from Jackson Lab were maintained in a Special Pathogen Free animal facility at Soochow University. All animal experiments comply with the ARRIVE guidelines and are carried out in accordance with the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the manuscript has followed such guidelines. All animal protocols were approved by the Institutional Laboratory Animal Care and Use Committee of Soochow University.
Angiotensin II Infusion Model
Osmotic minipumps (ALZET model 1007D, ALZA Corp) were implanted to infuse angiotensin II at a rate of 500 ng/kg/min or diluent as described previously (Song et al., 2005) . Seven days after implantation of the osmotic pumps, mice were anesthetized and muscles were removed, weighed, and snap-frozen and stored at − 80°C until processed.
Muscle Force Measurement
Mouse grip strength was measured daily for 3 consecutive days using a Grip Strength Meter (Ji-Nan Biotechnology, ShanDong, China). Each day, 5 grip strengths were assessed at 1 min intervals, and the average grip strength over 3 days was calculated. -Hydroxycholesterol (25-OHC, Sigma, Cat# H1015), 20α-hydroxycholesterol (20-OHC, Sigma, Cat# H6378) and 22(R)-hydroxycholesterol (22-OHC, Sigma, Cat# H9384), dissolved in 0.3% ethanol, were injected to C57BL/6 mice daily for 7 days (40 μg/mouse, i.p.). Control mice were injected with 0.3% ethanol.
In Vivo Delivery of Hydroxycholesterols
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Tibialis Anterior (TA) Muscle Injection of Lentivirus Overexpressing Ch25h
The mice were anesthetized. Each TA muscle was injected with 50 μl of concentrated viral preparations (7.0 × 10 7 transducing units/ml). The contralaterol TA muscles were injected with lentivirus carrying empty vector.
GSK3β Inhibitor TDZD-8 Treatment
Two hours before ang II infusion, the mice were injected with either TDZD-8 (Sigma, Cat# T8325, 5 mg/kg, 10% DMSO in PBS) or PBS containing 10% DMSO.
C2C12 Cell Culture
The mouse myoblast cell line C2C12 (ATCC Cat# CRL-1772, RRID:CVCL_0188) from American Type Culture Collection (Manassas, VA) was cultured in DMEM (ThermoFisher Scientific) containing 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin in 5% CO 2 at 37°C. To induce differentiation, DMEM containing 2% horse serum (Gibco, Cat# 16050122) was added to C2C12 cells when the density of cells reached 70-80%.
Satellite Cell Isolation
TA muscles were dissected, minced and digested with Collagenase D and Dispase type II (Roche) (Liu et al., 2016) . After digestion, the cells were resuspended in DMEM containing 1% glutamine and 10% FBS and plated on collagen coated dishes. Differentiation was induced by culturing the cells in DMEM containing 1% glutamine and 2% horse serum.
Myotube Calculation
Microscopic images of myotubes were captured using a digital camera mounted on a Leica microscope (DFC310 FX). Myotube diameter and length measurements were obtained using ImageJ software. Three short-axis measurements were taken along the length of a given myotube and averaged. The results were averaged from three independent experiments.
Construction of Lentivirus Overexpressing TNF-α and Ch25h
The LV5 plasmid (GenePharma, Shanghai, China) containing mouse TNF-α or Ch25h cDNA and packaging plasmids ΔR8.74, VSV-G and Rev were co-transfected into 293T cells as described previously (Zhou et al., 2014) . The packaging plasmids were provided by Dr. Yun Zhao, Soochow University.
Microarray Analysis
C2C12 myoblasts were cultured in DMEM containing 10% FBS and then treated with TNF-α (50 ng/ml) for 24 h. In separate experiments, C2C12 cells were cultured in DMEM containing 2% horse serum for 4 days and then treated with TNF-α (50 ng/ml) for 24 h. Total RNA was extracted from C2C12 cells using Trizol reagent. RNA samples were labeled and hybridized to Affymetrix Mouse Gene 2.0 ST Array, and analyzed by Shanghai Biotechnology Corporation. The microarray data have been submitted to the NCBI Archive, under accession number GSE92671.
Western Blot
Proteins extracted from gastrocnemius muscles were separated by SDS-PAGE and blotted to PVDF membranes (Millipore, ISEQ00010). The following antibodies were from Cell Signaling Technology: cleaved caspase-3 (Cat# 9664 RRID:AB_2070042), GAPDH (Cat# 2118S RRID:AB_10698756), Akt (Cat# 4691S RRID:AB_915783), p-Akt (Cat# Fig. 1 . TNFR1 knockout prevents ang II induced muscle wasting in mice. Changes in body weight of wild type C57BL/6 (A) and TNFR1KO mice (B) after ang II infusion for 7 days. n = 7 mice/group. P: pair-fed, sham infused mice, A: ang II infused mice. *P b 0.01. 4060S RRID:AB_916024), GSK3β (Cat# 9315S RRID:AB_490890), p-GSK3β (Cat# 5558S RRID:AB_10695601), Bad (Cat# 9268S RRID:AB_ 10695002), p-Bad (Cat# 5286S RRID:AB_2062129). The secondary antibody HRP-linked anti-rabbit IgG (Cat# A6154 RRID:AB_258284) was from Sigma. Rabbit anti-atrogin-1 (Cat# ab168372) and MuRF1 (Cat# 172479) antibodies were from Abcam.
Real-Time PCR
RNA was extracted using the Trizol reagent (Ambion), and cDNA was synthesized using the RevertAid First Strand cDNA Synthesis Kit (ThermoFisher Scientific). Real-time PCR was performed using the ABI 7500 Real Time PCR System with the following primers: Atrogin-1: 5′-GCAGAGAGTCGGCAAGTC3′, 5′-CAGGTCGGTGATCGTGAG3′; MuRF1: 5′-CAACCTGTGCCGCAAGTG3′, 5′-CAACCTCGTGCCTACAAGATG3′; TNF-α: 5′-CTTCTGTCTACTGAACTTCGGG3′, 5′-CAGGCTTGTCACTCGAATTTT G3′ Ch25h: 5′-CTGGGACACCATAAGGACAAG3′, 5′-AAGCCCACGTAAGTG ATGATAG3′; MyoD: 5′-TGCTCCTTTGAGACAGCAGA3′, 5′-AGTAGGG AAGTGTGCGTGCT3′ 18S: 5′-CTCTGTTCCGCCTAGTCCTG3′, 5′-AATGAGCCATTCGCAGTTTC 3′
Relative expression was calculated from cycle threshold (Ct; relative expression = 2 -(SΔCt − CΔCt) ) values using 18S as internal control for each samples. 
Immunostaining for MyoD, Myogenin and Pax7
Frozen sections (10 μm) were incubated with mouse anti-MyoD antibody (Thermo Fisher Scientific Cat# MA1-41017 RRID:AB_2282434) or mouse anti-myogenin (DSHB Cat# F5D RRID:AB_2146602), mouse anti-Pax7 antibody (DSHB Cat# pax7 RRID:AB_528428), and rabbit anti-laminin antibody (Sigma-Aldrich Cat# L9393 RRID:AB_477163). After washing, the sections were incubated with goat anti-mouse IgGAlexa Fluor® 488 conjugate (Thermo Fisher Scientific Cat# A-11001 RRID:AB_2534069) or goat anti-rabbit IgG-Alexa Fluor® 568 conjugate (Thermo Fisher Scientific Cat# A11011 RRID:AB_10584650). The sections were finally incubated with DAPI to stain nuclei.
ELISA
Serum TNF-α and 25-OHC levels were analyzed by ELISA per manufacturer's instruction (TNF-α ELISA kit: eBioscience Cat# BMS607/3 RRID:AB_2575663, San Diego, CA; 25-OHC ELISA kit: MyBioSource Cat# MBS9310855, Inc. San Diego, CA).
Cross Sectional Area (CSA) of Myofibers
Gastrocnemius muscles were removed, frozen in isopentane cooled in liquid nitrogen and sectioned in a microtome cryostat.
For fiber typing, unfixed sections were incubated in antibodies against myosin heavy chain (MyHC) types 1, 2a and 2b (1:100) from Developmental Studies Hybridoma Bank (Cat# BA-D5 RRID:AB_ 2235587, Cat# SC-71 RRID:AB_2147165 and Cat# BF-F3 RRID:AB_ 2266724). MyHC type 2 × expression was inferred from unstained fibers. Fluorescence-conjugated secondary antibodies to various mouse immunoglobulin subtypes from Thermo Fisher Scientific (Goat antiMouse IgG2b AF647, Cat# A-21242 RRID:AB_2535811, 1:250, Goat anti-Mouse IgG1 AF488, Cat# A-21121 RRID:AB_2535764, 1:500, Goat anti-Mouse IgM AF546, Cat# A-21045 RRID:AB_2535714, 1:250) were applied to visualize MyHC expression. Specimens were analyzed using an OLYMPUS confocal microscope (FV1000). CSA was quantified using ImageJ software by an observer blinded to treatment.
Ch25h Promoter Construct
The PGL4.17 plasmid (provided by Dr. Quansheng Zhou, Soochow University) carrying the Ch25h promoter (− 300 bp from the start codon), along with a Renilla luciferase control reporter (RL-TK) plasmid was transfected into C2C12 cells by lipofectamine 2000 (Invitrogen, Cat# 11668-019). TNF-α (10 ng/ml) was added to the cells 24 h after transfection, and luciferase activity was detected 8 h after the addition of TNF-α by a luminometer (Luminoskan® Ascent, Thermo Scientific).
TUNEL Staining
Frozen sections were fixed by 4% Paraformaldehyde for 20 min at room temperature. After washing between each step, the sections were blocked in 3% H 2 O 2 methanol, permeabilized in 0.1% Triton X-100 and then incubated with TUNEL reaction mixture provided by In Situ Cell Death Detection Kit, POD (Roche, Cat# 11684817910). The sections were incubated with DAPI to stain nuclei.
Statistical Analysis
Data were presented as means ± SD. The t-test was used to determine the significance of the differences between two groups. Multiple comparisons were analyzed by ANOVA with a post-hoc analysis by the Student-Newman-Keuls test. P b 0.05 was considered statistically significant.
Results
Angiotensin II-induced Muscle Wasting is Mediated by TNF-α Signaling Pathway
To address whether TNF-α is a mediator of ang II induced muscle wasting, we infused wild type C57BL/6 or TNFR1KO mice with 500 ng/ kg/min ang II or vehicle for 7 days as described previously (Song et al., 2005) . In C57BL/6 mice, ang II infusion led to reduced body weight (Fig.  1A) , grip strength ( Fig. 2A) , muscle weight ( Fig. 2B-D) and cross sectional area (CSA) of myofibers (Fig. 3A,B) , accompanied by elevated serum levels of TNF-α (Fig. 3C) . However, ang II induced body weight reduction, decreased grip strength and muscle loss were prevented in TNFR1KO mice (Figs. 1B, 2-3) despite the increase of TNF-α in the sera of the TNFR1KO mice (Fig. 3C ). We performed additional experiments to compare ang II infused mice with ad libitum untreated animals. The results showed decreased body weight, grip strength and muscle weight in ang II infused C57BL/6 mice but not in TNFR1KO mice . In contrast to skeletal muscles, the heart weight was increased in ang II infused mice ( Supplementary Fig. 3 ). Our observation is consistent with previous study that heart weights of ang II infused rats were higher than those in controls (Brink et al., 2001) . These findings suggest that TNF-α signaling plays a critical role in ang II induced muscle atrophy. Impaired IGF-1 signaling is a common feature in several wasting conditions. To understand why loss of muscle mass was blunted in TNFR1KO mice, we examined key proteins involved in IGF-1 signaling pathway. Westernblot analysis shows that levels of p-Akt and p-GSK3β were decreased in gastrocnemius muscles from ang II infused wild type C57BL/6, but not from TNFR1KO mice (Fig.  4A-C) , suggesting that ang II induced reduction of p-Akt and p-GSK3β is mediated by TNF-α. Reduced phosphorylation of GSK3β leads to its activation, which promotes protein degradation via ubiquitin proteasome pathway (Verhees et al., 2011) . We next analyzed expression of atrogin-1 and MuRF1, which are ubiquitin ligases implicated in muscle wasting. Westernblot results showed increased atrogin-1 and MuRF1 expression in the gastrocnemius muscle of C57BL6, but not in TNFR1KO mice (Fig.  4A, D-E) , suggesting that ang II induced activation of ubiquitin proteasome pathway is mediated by TNF-α signaling via TNFR1. We have shown previously that caspase-3 mediated apoptosis played a role in ang II induced muscle wasting (Song et al., 2005) . We now provide evidence that the expression of cleaved caspase-3 as well as TUNEL positive cells are increased in muscles from ang II infused C57BL/6 mice, but not from TNFR1KO mice (Figs. 4F, 5A ). These results suggest that TNF-α is the mediator of ang II induced apoptosis in skeletal muscle. Ang II infusion also caused reduction of MyoD, myogenin and Pax7 expression in wild-type C57BL/6 but not in TNFR1KO mice (Fig. 5B-D) , suggesting that myogenic differentiation is impaired by ang II.
Ch25h is the Downstream Target of TNF-α that Mediate Ang II's Wasting Effect
To explore the mechanisms underlying ang II's wasting effect, we studied the impact of ang II treatment on TNF-α expression using a myoblast line C2C12. Consistent with our in vivo data, ang II treatment resulted in increased expression of TNF-α (Fig. 6A) , reduced expression of MyoD (Fig. 6B) and inhibition of myogenic differentiation of both C2C12 cells (Fig. 7) and primary satellite cells ( Supplementary Fig. 4 ). We also isolated satellite cells from ang II treated mice and then cultured the cells in the absence of ang II in order to determine whether inhibitory effect of ang II on satellite cell differentiation can be reversed. Our data showed that the differentiation of satellite cells from ang II treated mice was normal, suggesting that the impairment of myogenic differentiation is 'environment-dependent' (Supplementary Fig. 5 ). We performed microarray analysis in order to identify genes under TNF-α regulation in C2C12 cells. In response to TNF-α treatment, cholesterol 25-hydroxylase (Ch25h) was upregulated 35.6-and 22.2-fold, in C2C12 cells cultured in 10% FBS and 2% horse serum, respectively (Supplementary Tables 1-2) . Real time PCR analysis confirmed microarray findings and showed higher Ch25h mRNA expression compared to microarray results (Fig. 8A ). Ch25h is of particular interest because it has been shown previously that 25-hydroxycholeterol (25-OHC), the product of Ch25h, inhibits myoblast fusion (Cornell et al., 1980; Lowrey and Horwitz, 1982) , and induces mitochondria-dependent apoptosis via activation of GSK3β (Choi et al., 2008) . To define the relationship between TNF-α and Ch25h, we transfected C2C12 cells with a lentivirus over-expressing TNF-α. Overexpression of TNF-α led to inhibition of myogenic differentiation (Fig. 8B) , associated with a significant increase of Ch25h mRNA expression (Fig. 9A) .
Ch25h catalyzes the formation of 25-OHC from cholesterol. We analyzed the levels of 25-OHC in the serum samples from ang II infused mice by ELISA. The result showed that ang II infusion induced a significant increase of 25-OHC in C57BL/6 but not in TNFR1KO mice (Fig. 9B) . Consistent with these findings, ang II treatment increased Ch25h mRNA expression level in C2C12 cells (Fig. 9C) .
To assess whether TNF-α affects Ch25h transcription, we transfected C2C12 cells with a plasmid expressing Ch25h-driving luciferase (PGL4.17-Ch25h), along with a control plasmid expressing Renilla luciferase (RL-TK). Luciferase assay revealed that Ch25h transcriptional activity increased significantly upon TNF-α stimulation (Fig. 9D) . We then constructed a plasmid over-expressing Ch25h in order to investigate the effect of Ch25h expression on muscle wasting. The increased mRNA level of Ch25h in C2C12 cells transfected with Ch25h plasmid was confirmed by real-time PCR (Fig. 10A) . Over-expression of Ch25h in C2C12 cells resulted in inhibition of myogenic differentiation (Fig. 10B ) and decreased expression of MyoD (Fig. 10C) . Furthermore, the mRNA expression levels of atrogin-1 and MuRF1 are increased in C2C12 cells over-expressing Ch25h (Fig. 10D, E) . These results show that Ch25h induced muscle wasting is caused by inhibition of myogenic differentiation and activation of the ubiquitin/proteasome pathway.
25-OHC Induces Muscle Atrophy via Activation of GSK3β in C57BL/6 Mice
Next, we asked whether 25-OHC could induce muscle wasting in animals. We injected 25-OHC to C57BL/6 mice and found that body and muscle weights were deceased in these mice (Fig. 11) . To examine the specificity of the response, 22-OHC and 20-OHC, which are sterols structurally similar to 25-OHC, were also injected to C57BL/6 mice separately. These two sterols did not induce muscle wasting in mice (Fig. 11) . It has been shown previously that 25-OHC induces mitochondria-dependent apoptosis via activation of GSK3β and subsequent activation of caspase-3 in PC12 cells (Choi et al., 2008) . These previous studies prompted us to determine whether apoptosis plays a role in 25-OHC induced muscle wasting. Westernblot analysis revealed the levels of pAkt, pGSK3β, p-BAD were decreased, whereas levels of cleaved caspase-3 were increased in gastrocnemius muscles from mice received 25-OHC, but not from mice that received 20-OHC, 22-OHC or control treatment (Fig.  12A) , suggesting that inactivation of Akt and subsequent activation of GSK3β led to Bad/caspase-3 mediated apoptosis. 25-OHC treatment also resulted in increased expression of atrogin-1 and MuRF1 (Fig.  12A) . These results indicate that both ubiquitin-proteosome pathway and apoptosis are involved in 25-OHC induced muscle atrophy. 25-OHC treatment reduced MyoD and Pax7 expression compared to control, 20-OHC and 22R-OHC (Fig. 12B-C) , suggesting that myogenic differentiation was impaired by 25-OHC. To further confirm the role of Ch25h in ang II induced muscle loss, we injected lentivirus that overexpress 25-hydroxylase gene into TA muscle of C57BL/6 mice, the contralaterol TA muscles were injected with lenti virus carrying empty vector. The results showed that 25-hydroxylase overexpression in vivo induces muscle atrophy (Fig. 12D) . Compared to the control, TA muscles injected with 25-hydroxylase showed reduced expression of MyoD, myogenin, Pax7, but increased TUNEL positive cells (Fig. 13) .
Inhibition of GSK3β Prevents Ang II Induced Muscle Wasting
To determine if a therapeutic strategy might be developed to interfere with muscle wasting when GSK3β is activated, we evaluated TDZD-8, a highly selective small molecule inhibitor of GSK3β that binds to the kinase site of GSK3β. Mice were injected with either TDZD-8 or DMSO, and randomly divided into ang II infusion or pair-fed control groups. After 7 days, both body weights and muscle weight were reduced in ang II infused and DMSO treated mice compared to pair-fed control groups (Fig. 14A-D) . By contrast, both body weights and muscle weight were preserved in TDZD-8 treated group (Fig. 14A-D) . Westernblot analysis showed that ang II induced upregulation of atrogin-1, MuRF1 and caspase-3 cleavage was prevented by TDZD-8 (Fig. 14E) .
Discussion
Patients with chronic illness such as end stage heart failure, sarcopenia and cancer often develop cachexia, which limit their daily activity and reduces their tolerance to therapy. Cachetic conditions are associated with increased serum angiotensin II (Du Bois et al., 2015; Penafuerte et al., 2016) and TNF-α levels (Martins et al., 2014; Talar-Wojnarowska et al., 2009 ). Injection of TNF-α reduces the force development in the diaphragm of mice (Mangner et al., 2013) . However, the relationship between ang II and TNF-α and their signaling pathways leading to cachexia remain unknown, which hampers the development of effective therapeutic strategies. In the present study, we discovered that TNF-α is the mediator of ang II induced muscle loss and we further identified Ch25h as the down stream molecule that mediates TNF-α's wasting effect. Administration of 25-OHC, the product of Ch25h, induces muscle atrophy in mice through activation of GSK3β signaling pathway. These findings identify 25-OHC as an inducer of muscle atrophy.
Ch25h catalyze the formation of 25-OHC from dietary cholesterol, leading to decreased activity of enzymes involved in cholesterol synthesis. 25-OHC was initially discovered as a regulator of lipid metabolism, and has been implicated in the development of atherosclerosis (Brown and Jessup, 1999) . Recent studies indicate that 25-OHC promotes foam cell formation and inflammation (Gold et al., 2014) , but the role of 25-OHC in muscle wasting has never been reported before. Evidence for the 25-OHC dependent pathway that initiate loss of muscle mass was obtained from three experimental models: microarray, realtime PCR analysis and luciferase assay confirmed that Ch25h is the down stream target of TNF-α in C2C12 cells; ang II infusion led to the release of 25-OHC in wild type C57BL/6 but not in TNFR1KO mice; 25-OHC injection cause muscle wasting in C57BL/6 mice.
How does 25-OHC influence muscle wasting? Our results show that both ang II infusion and 25-OHC activate GSK3β, which induces muscle loss by three possible mechanisms: (1) activation of ubiquitin/proteasome pathway through inhibition of IGF-1/Akt signaling; (2) activation of mitochondria dependent apoptosis; (3) inhibition of myogenic differentiation.
It has been shown that 25-OHC can block IGF-1 stimulated phosphorylation of Akt and cell survival because 25-OHC inhibits the biosynthesis of cholesterol which is required for activation of IGF-1/Akt pathway (Romanelli et al., 2009 ). Low p-Akt level causes reduced phosphorylation of GSK3β, which leads to GSK3β activation and subsequent Twenty-four hours after transfection, the cells were treated with or without TNF-α (10 ng/ml). Dual luciferase activity was measured 8 h after the treatment; n = 3, **P b 0.01, TNF-α vs. control. upregulation of atrogin-1 and MuRF1. Indeed, we found that 25-OHC induced muscle wasting is characterized by reduced levels of p-Akt and p-GSK3β and increased levels of atrogin-1, MuRF-1 and caspase-3, which are in line with our findings from ang II induced muscle wasting. Under physiological conditions, GSK3β is phosphorylated at Ser9 and inactivated by Akt. However, in pathological conditions where IGF-1/ Akt signaling is impaired, GSK3β is dephosphorylated at Ser9 and induces muscle loss via up-regulation of atrogin-1, MuRF1 and activation of the ubiquitin-proteasome pathway (Pansters et al., 2015) . Activation of GSK-3β is implicated in various forms of muscle wasting including disuse (Pansters et al., 2015) and burn induced muscle loss (Fang et al., 2007) . Muscle-specific GSK-3β deletion promotes the recovery of disuse-induced atrophy (Pansters et al., 2015) . Pharmacological inhibition of GSK-3β prevents TNF-α induced muscle loss in a guinea pig model of pulmonary inflammation associated muscle atrophy (Verhees et al., 2013) . Knockdown of GSK-3β using small interfering RNA suppressed both basal and dexamethasone-induced atrogin-1 and MuRF1 expression in C2C12 myotubes (Verhees et al., 2011) . By contrast, activation of GSK-3β leads to up-regulation of atrogin-1/ MuRF1 and muscle atrophy (Verhees et al., 2011) . Atrogin-1 and MuRF-1 are E3 ubiquitin ligases which are expressed only in skeletal and smooth muscle cells. These two ubiquitin ligases have been implicated in various types of muscle wasting models and deletion of these genes can prevent muscle atrophy. Our findings that GSK3β inhibitor TDZD-8 pretreatment prevented ang II induced up-regulation of atrogin-1, MuRF-1 and muscle wasting further confirmed the role of GSK3β in mediating ang II's wasting effect. TDZD-8 is a highly specific and potent inhibitor of GSK3β. Previous studies showed that TDZD-8 prevented the increase in atrogin-1 and MuRF1 mRNA levels in dexamethasone-treated myotubes , and inhibited protein breakdown in muscles from burned rats (Fang et al., 2005) .
Recent studies suggest that activation of GSK3β could also induce apoptosis. In a liver ischemia reperfusion (IR) model, TDZD-8 treatment prevented IR induced caspase-3 activation and apoptosis (Rocha et al., 2015) , suggesting a role of GSK3β in mediating the activation of caspase-3 dependent apoptotic pathway. Suppression of GSK-3β activation by M-cadherin protects myoblasts against mitochondria-associated apoptosis during myogenic differentiation (Wang et al., 2011) . Inactivation of GSK-3β facilitates recovery of mitochondria potential by suppressing ROS production, leading to cytoprotection from oxidant stress-induced cell death (Sunaga et al., 2014) . Along this line, ang II infusion was shown to induce ROS production and mitochondria dependent apoptosis in mouse skeletal muscle (Kadoguchi et al., 2015) . Bad is an important protein involved in mitochondrial dependent apoptosis. Bad induces apoptosis by displacing Bax from binding to Bcl-2. Once dissociated from Bcl-2, Bax will translocate into mitochondria and triggers the release of cytochrome c. Anti-apoptotic factors such as IGF-1 inhibits the apoptotic activity of Bad by activating Akt, which phosphorylates Bad at Ser136. Our data suggest that 25-OHC induced muscle atrophy may be partially mediated by mitochondria dependent apoptosis through de-phosphorylation and activation of Bad. 25-OHC was shown to induce apoptosis in macrophages through activation of Bad by degrading Akt (Rusinol et al., 2004) . We now provided evidence that 25-OHC injection resulted in reduced levels of p-Bad and increased levels of cleaved caspase-3 in mouse gastrocnemius muscles. In addition to activation of Bad, 25-OHC has also been shown to induce apoptosis in cardiomyocytes, smooth muscle cells, and PC-12 cells via the production of reactive oxygen species and activation of GSK3β (Appukuttan et al., 2013; Choi et al., 2008; Lee da et al., 2015; Rosca et al., 2012; Sekiya et al., 2014) .
GSK3β is a negative regulator of muscle differentiation and growth, and its knockdown stimulates myogenic differentiation of skeletal muscle cells (van der Velden et al., 2008) . Pharmacological inhibition of GSK3β attenuates TNF-α and glucocorticoid induced suppression of MyoD expression and myotube formation in C2C12 and primary satellite cells Verhees et al., 2013) . TDZD-8 also improved muscle strength and Pax7 expression (a marker for satellite cells) in HSA LR mice, a mouse model of myotonic dystrophy (Jones et al., 2012) .
These studies suggest that GSK3β inhibits muscle regeneration by inhibiting activation of satellite cells. Indeed, our in vivo data showed reduced MyoD expression in muscles from mice received either ang II infusion or 25-OHC, accompanied by reduced expression levels of p-GSK3β. These results demonstrate that 25-OHC induced muscle wasting is mediated in part by inhibition of myogenic differentiation via activation of GSK3β.
How could ang II stimulate the production of 25-OHC? A previous study demonstrated that transcription and translation of Ch25h are increased in response to TNF-α in glioblastoma cell lines (Eibinger et al., 2013) . Indeed, our results showed that serum levels of 25-OHC were increased in ang II infused wild type C57BL/6 mice, but not in ang II infused TNFR1KO mice, suggesting that ang II induced secretion of 25-OHC is mediated by TNF-α signaling through TNFR1. Luciferase assay confirmed that Ch25h transcriptional activity increased significantly upon TNF-α stimulation in C2C12 cells.
Our results have identified a pathway that stimulates muscle wasting in response to ang II. The pathway is mediated by TNF-α through its type 1 receptor and subsequent activation of Ch25h and release of 25-OHC, which in turn impairs Akt signaling, leading to activation of GSK3β. Previous studies have shown that ang II not only contribute to cardiac cachexia, but also play an important role in muscle wasting associated with sarcopenia and cancer. Age-related increase in ang II level contributes to the development of sarcopenia. Losartan, an ang II type I receptor blocker significantly improved exercise capacity in aged mice (Lin et al., 2014) and prevented disuse atrophy in aged mice that were subjected to hindlimb immobilization (Burks et al., 2011) . Animal studies showed that ACE inhibitor could attenuate weight loss in mice bearing MAC16 tumor (Sanders et al., 2005) . Clinical studies showed that cancer cachexia is associated with elevated plasma levels of ang II (Penafuerte et al., 2016) . Therefore, our work laid the foundation for exploiting Ch25h as a target for the development of specific therapies for treating cachexia associated with heart failure, sarcopenia and cancer.
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